Literature DB >> 25406425

Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: a multicentre study on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours of the Lung Working Group†.

Pier Luigi Filosso1, Ottavio Rena2, Francesco Guerrera3, Paula Moreno Casado4, Dariusz Sagan5, Federico Raveglia6, Alessandro Brunelli7, Stefan Welter8, Lucile Gust9, Cecilia Pompili7, Caterina Casadio2, Giulia Bora3, Antonio Alvarez4, Wojciech Zaluska10, Alessandro Baisi6, Christian Roesel8, Pascal Alexandre Thomas9.   

Abstract

OBJECTIVES: In 2012, the European Society of Thoracic Surgeons (ESTS) created the Lung Neuroendocrine Tumors Working Group (NETs-WG) with the aim to develop scientific knowledge on clinical management of such rare neoplasms. This paper outlines the outcome and prognostic factors of two aggressive NETs: atypical carcinoids (ACs) and large-cell neuroendocrine carcinomas (LCNCs).
METHODS: Using the ESTS NETs-WG database, we retrospectively collected data on 261 patients in seven institutions in Europe, between 1994 and 2011. We used a Cox regression model to evaluate variables affecting patient survival and disease-free survival. Univariate and multivariate analysis were also carried out.
RESULTS: Five-year overall survival rates for ACs and LCNCs were 77 vs 28% (P < 0.001), respectively. We found that for ACs, age (P < 0.001), tumour size (P = 0.015) and sub-lobar surgical resection (P = 0.005) were independent negative prognostic factors; for LCNCs, only pTNM stage III tumours (P = 0.016) negatively affected outcome in the multivariate analysis. Local recurrences and distant metastases developed in 93 patients and were statistically more frequent in LCNCs (P = 0.02).
CONCLUSIONS: The biological aggressiveness of ACs and LCNCs has been demonstrated with this study. Our aim is to confirm these results with enhanced data collection through the ESTS NETs database.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Atypical carcinoid; Large-cell neuroendocrine carcinoma; Lung; Metastasis; Neuroendocrine tumour; Recurrence; Surgery; Survival

Mesh:

Year:  2014        PMID: 25406425     DOI: 10.1093/ejcts/ezu404

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  18 in total

Review 1.  The European Society of Thoracic Surgeons (ESTS) lung neuroendocrine tumors (NETs) database.

Authors:  Pier Luigi Filosso; Pierre Emmanuel Falcoz; Paolo Solidoro; Danilo Pellicano; Stefano Passani; Francesco Guerrera; Enrico Ruffini
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  European Society of Thoracic Surgeons big data utilization-part 1: research interest for the thoracic community.

Authors:  Michele Salati
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 3.  Treatment of lung large cell neuroendocrine carcinoma.

Authors:  Giuseppe Lo Russo; Sara Pusceddu; Claudia Proto; Marianna Macerelli; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Rosaria Gallucci; Nicoletta Zilembo; Marco Platania; Roberto Buzzoni; Filippo de Braud; Marina Chiara Garassino
Journal:  Tumour Biol       Date:  2016-03-04

4.  Endobronchial Treatment for Bronchial Carcinoid: Patient Selection and Predictors of Outcome.

Authors:  Ellen M B P Reuling; Chris Dickhoff; Peter W Plaisier; Veerle M H Coupé; Albert H A Mazairac; Rutger J Lely; H Jaap Bonjer; Johannes M A Daniels
Journal:  Respiration       Date:  2018-02-12       Impact factor: 3.580

5.  Large Cell Neuroendocrine Tumor Size >3 cm Negatively Impacts Long-Term Outcomes After R0 Resection.

Authors:  Maria Cattoni; Eric Vallières; Lisa M Brown; Amir A Sarkeshik; Stefano Margaritora; Alessandra Siciliani; Pier Luigi Filosso; Francesco Guerrera; Andrea Imperatori; Nicola Rotolo; Farhood Farjah; Grace Wandell; Kimberly Costas; Catherine Mann; Michal Hubka; Stephen Kaplan; Alexander S Farivar; Ralph W Aye; Brian E Louie
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

Review 6.  Multidisciplinary management of advanced lung neuroendocrine tumors.

Authors:  Pier Luigi Filosso; Piero Ferolla; Francesco Guerrera; Enrico Ruffini; William D Travis; Giulio Rossi; Paolo Olivo Lausi; Alberto Oliaro
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

Review 7.  Surgical Principles in the Management of Lung Neuroendocrine Tumors: Open Questions and Controversial Technical Issues.

Authors:  Debora Brascia; Giuseppe Marulli
Journal:  Curr Treat Options Oncol       Date:  2022-10-21

8.  Prognostic significance of histopathological factors in survival and recurrence of atypical carcinoid tumours.

Authors:  Eva-María García-Fontán; Miguel-Ángel Cañizares-Carretero; Montserrat Blanco-Ramos; Jose-María Matilla-González; Rommel Carrasco-Rodríguez; Francisco Barreiro-Morandeira; Mariano García-Yuste
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-27

9.  Administrative and clinical databases: General thoracic surgery perspective on approaches and pitfalls.

Authors:  Biniam Kidane; Elliot Wakeam; Robert A Meguid; David D Odell
Journal:  J Thorac Cardiovasc Surg       Date:  2021-03-19       Impact factor: 6.439

10.  Surgical treatment of low and intermediate grade lung net.

Authors:  Mariano García-Yuste; José María Matilla; Miguel Angel Cañizares; Laureano Molins; Ricardo Guijarro
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.